143 related articles for article (PubMed ID: 14745155)
1. Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab).
Nakagawa Y; Ikeda U; Hirose M; Ubukata S; Katsuki TA; Kaminishi Y; Saito T; Hironaka M; Izumi T; Shimada K
Circ J; 2004 Feb; 68(2):172-3. PubMed ID: 14745155
[TBL] [Abstract][Full Text] [Related]
2. Primary cardiac lymphoma detected by myocardial perfusion imaging: case report.
Trost B; Croft L; Nair A; Henzlova M
J Nucl Cardiol; 2007 Jan; 14(1):e6-10. PubMed ID: 17276296
[No Abstract] [Full Text] [Related]
3. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
[TBL] [Abstract][Full Text] [Related]
4. Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab.
Natkunam Y; Stanton TS; Warnke RA; Horning SJ
Clin Lymphoma; 2001 Dec; 2(3):185-7. PubMed ID: 11779297
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of primary cardiac B-cell lymphoma: depiction at multislice computed tomography and magnetic resonance imaging.
Sato Y; Matsumoto N; Kinukawa N; Matsuo S; Komatsu S; Kunimasa T; Yoda S; Tani S; Takayama T; Kasamaki Y; Kunimoto S; Furuhashi S; Takahashi M; Saito S
Int J Cardiol; 2006 Oct; 113(1):E26-9. PubMed ID: 17049383
[TBL] [Abstract][Full Text] [Related]
6. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
Hao LC; Zhang LZ
Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
[No Abstract] [Full Text] [Related]
7. Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation.
Nonami A; Takenaka K; Kamezaki K; Miyamoto T; Harada N; Nagafuji K; Teshima T; Harada M
Int J Hematol; 2007 Apr; 85(3):264-6. PubMed ID: 17483065
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
9. Rituximab.
Doan T; Massarotti E
Drugs Today (Barc); 2005 Dec; 41(12):785-97. PubMed ID: 16474854
[TBL] [Abstract][Full Text] [Related]
10. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
11. 4. Antibody therapy for malignant lymphoma.
Tobinai K
Intern Med; 2007; 46(2):99-100. PubMed ID: 17220608
[TBL] [Abstract][Full Text] [Related]
12. Dramatical improvement of chemoresistant bone lymphoma with rituximab.
Achemlal L; Mikdame M; Nouijai A; Bezza A; El Maghraoui A
Clin Rheumatol; 2006 May; 25(3):394-5. PubMed ID: 16247586
[TBL] [Abstract][Full Text] [Related]
13. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
Kennedy GA; Tey SK; Cobcroft R; Marlton P; Cull G; Grimmett K; Thomson D; Gill D
Br J Haematol; 2002 Nov; 119(2):412-6. PubMed ID: 12406079
[TBL] [Abstract][Full Text] [Related]
14. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection.
Spina M; Sparano JA; Jaeger U; Rossi G; Tirelli U
AIDS; 2003 Jan; 17(1):137-8. PubMed ID: 12478085
[No Abstract] [Full Text] [Related]
15. [A case of malignant lymphoma associated with diffuse pulmonary involvement successfully treated with rituximab].
Kataoka T; Ishida Y; Kurokawa R; Takeshita S; Ohta K; Nishimura Y; Yokoyama M
Nihon Kokyuki Gakkai Zasshi; 2003 Dec; 41(12):899-904. PubMed ID: 14727553
[TBL] [Abstract][Full Text] [Related]
16. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
17. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
18. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.
Pels H; Schulz H; Schlegel U; Engert A
Onkologie; 2003 Aug; 26(4):351-4. PubMed ID: 12972702
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in a patient with acute renal failure due to B-cell lymphomatous infiltration of the kidneys.
Tokar M; Rogachev B; Levi I; Yerushalmi R; Ariad S; Geffen DB
Leuk Lymphoma; 2004 Apr; 45(4):819-20. PubMed ID: 15160963
[TBL] [Abstract][Full Text] [Related]
20. Sequential application of chemotherapy and monoclonal CD 20 antibody: successful treatment of advanced composite-lymphoma.
Linck D; Lentini G; Tiemann M; Fauser AA; Parwaresch R; Basara N
Leuk Lymphoma; 2005 Feb; 46(2):285-8. PubMed ID: 15621815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
